fulranumab

A fully human monoclonal antibody directed against nerve growth factor (NGF) with potential analgesic activity. Upon administration, fulranumab binds… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
024620122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND This study was designed to evaluate the efficacy and safety of fulranumab, a fully human monoclonal antibody directed… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2017
2017
Results: The US Food and Drug Administration placed a clinical hold (December 23, 2010) on all trials of antinerve growth factor… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
OBJECTIVE To evaluate the long-term safety and efficacy of fulranumab in patients with knee or hip pain caused by moderate-to… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
OBJECTIVE Fulranumab is an antibody that specifically neutralizes the biological activity of human nerve growth factor. This… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2016
2016
PURPOSE Fulranumab is an investigational, fully human recombinant monoclonal antibody (IgG2) that neutralizes the biological… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • table III
Is this relevant?
2016
2016
AIMS The efficacy and safety of monotherapy with fulranumab, a monoclonal antibody that neutralises human nerve growth factor… (More)
Is this relevant?
Review
2015
Review
2015
To evaluate the efficacy and safety of anti-NGF antibody treatment in hip and knee osteoarthritis (OA), a systematic review and… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • table III
Is this relevant?
2014
2014
OBJECTIVE To assess efficacy and safety of fulranumab, a fully human monoclonal antibody against nerve growth factor, in patients… (More)
Is this relevant?
2014
2014
Fulranumab, a human IgG2 monoclonal antibody that neutralizes nerve growth factor (NGF), is currently in development for the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Nerve growth factor (NGF) is increased in chronic pain conditions. This study examined analgesic efficacy and safety of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?